Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will be allocated towards research and development, regulatory filing, and commercialization efforts.
Established in 2019, Matridx Bio has amassed a portfolio of medical device licenses centered around high-throughput next-generation sequencing (NGS) and CRISPR/Cas technologies. These technologies address a spectrum of infections, from critical and complex illnesses to moderate and common infections. The company’s one-stop fully automated mNGS product solution has been deployed in national and local disease prevention and control centers since 2020.- Flcube.com
